ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination
Neuro-Oncology Advances · 01.01.2023 · 5 (1)
DOI: 10.1093/noajnl/vdad095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 07.08.2023. Verfasst von Jill K Jones und 14 weiteren Autor:innen. Beteiligte Einrichtung: Harvard/MIT MD-PhD Program, Boston, MA, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Medulloblastoma is the most common malignant pediatric brain tumor, and leptomeningeal dissemination (LMD) of medulloblastoma both portends a poorer prognosis at diagnosis and is incurable at recurrence. The biological mechanisms underlying LMD are unclear. The Abelson (ABL) tyrosine kinase family members, ABL1 and ABL2, have been implicated in cancer cell migration, invasion, adhesion, metastasis, and chemotherapy resistance, and are upstream mediators of the oncogene c-MYC in fibroblasts and lung cancer cells. However, their role in medulloblastoma has not yet been explored. The purpose of this work was to elucidate the role of ABL1/2 in medulloblastoma LMD.
Methods
ABL1 and ABL2 mRNA expression of patient specimens was analyzed. shRNA knockdowns of ABL1/2 and pharmacologic inhibition of ABL1/2 were used for in vitro and in vivo analyses of medulloblastoma LMD. RNA sequencing of ABL1/2 genetic knockdown versus scrambled control medulloblastoma was completed.
Results
ABL1/2 mRNA is highly expressed in human medulloblastoma and pharmacologic inhibition of ABL kinases resulted in cytotoxicity. Knockdown of ABL1/2 resulted in decreased adhesion of medulloblastoma cells to the extracellular matrix protein, vitronectin (P = .0013), and significantly decreased tumor burden in a mouse model of medulloblastoma LMD with improved overall survival (P = .0044). Furthermore, both pharmacologic inhibition of ABL1/2 and ABL1/2 knockdown resulted in decreased expression of c-MYC, identifying a putative signaling pathway, and genes/pathways related to oncogenesis and neurodevelopment were differentially expressed between ABL1/2 knockdown and control medulloblastoma cells.
Conclusions
ABL1 and ABL2 have potential roles in medulloblastoma LMD upstream of c-MYC expression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harvard/MIT MD-PhD Program, Boston, MA, USA.
- Department of Neurosurgery, Duke University, Durham, NC, USA.
- Institut Curie, PSL Research University, Paris, France.
- Inserm, U900, Paris, France.
- MINES ParisTech, CBI - Centre for Computational Biology, PL Research University, Paris, France.
- Duke University Molecular Physiology Institute, Durham, NC, USA.
ORCID-Profile: Eric M Thompson
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Jones, J. K., Zhang, H., Lyne, A. M., Cavalli, F. M. G., Hassen, W. E., Stevenson, K., Kornahrens, R., Yang, Y., Li, S., Dell, S., Reitman, Z. J., Herndon, J. E., Hoj, J., Pendergast, A. M., & Thompson, E. M. (2023). ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad095
Vancouver
Jones JK, Zhang H, Lyne AM, Cavalli FMG, Hassen WE, Stevenson K, et al. ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad095
BibTeX
@article{Jones2023,
author = {Jones, Jill K and Zhang, Hengshan and Lyne, Anne-Marie and Cavalli, Florence M G and Hassen, Wafa E and Stevenson, Kevin and Kornahrens, Reb and Yang, Yuanfan and Li, Sean and Dell, Samuel and Reitman, Zachary J and Herndon, James E and Hoj, Jacob and Pendergast, Ann Marie and Thompson, Eric M},
title = {ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination},
journal = {Neuro-Oncology Advances},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/noajnl/vdad095}
}
EUVIMED